Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-57536
Perry, J R; Wick, W; Weller, M (2011). Optimizing the use of alkylators in neuro-oncology. Educational Book, 2001:61-64.
For more than three decades, alkylating agents have been the most widely used class of chemotherapeutic agents for the treatment of glial brain tumors. Today, concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma. Temozolomide alone or in combination with radiotherapy is being explored in ongoing trials in newly diagnosed patients with low-grade and anaplastic glioma. Rechallenge with alternative dosing schedules of temozolomide is a valid treatment option in recurrent, temozolomide-pretreated patients with glioblastoma, and nitrosourea compounds are alternative treatment options in this setting, in addition to novel, mostly antiangiogenic agents, notably bevacizumab. Moreover, nitrosoureas have become the gold standard comparator arm for the evaluation of novel treatments in recurrent glioblastoma.
37 downloads since deposited on 29 Jan 2012
9 downloads since 12 months
|Item Type:||Journal Article, not refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|DDC:||610 Medicine & health|
|Deposited On:||29 Jan 2012 11:37|
|Last Modified:||04 Feb 2014 15:50|
|Publisher:||American Society of Clinical Oncology|
|Series Name:||Educational Book|
|Additional Information:||Kongressbeitrag anlässlich des 2011 ASCO Annual Meeting, June 3 - 7, 2011, Chicago, Ill.|
|Related URLs:||http://www.asco.org/ASCOv2/Education+%26+Training/Educational+Book (Publisher)|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page